Western Midstream Partners (NYSE:WES) Q4 2025 Earnings call February 19, 2026 10:00 AM ET Speaker6Good morning. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the Western Midstream Partners fourth quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply pres ...

Brookdale Senior Living (NYSE:BKD) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchDawn L. Kussow - EVP and CFOMary Sue Patchett - COOMike Grant - VP of Investor RelationsNick Stengle - CEOConference Call ParticipantsBen Hendrix - VP and Equity Research AnalystBrian Tanquilut - Senior Equity Research AnalystJoanna Gajuk - Equity Research AnalystJosh Raskin - Managing Director and AnalystOperatorGood morning. My name is Jordan, and I'll be your ...

Core Insights - Williams (WMB) is projecting a compound annual growth rate (CAGR) of over 10% for adjusted EBITDA through 2030, driven by power and transmission projects [1] - The company has a significant backlog of opportunities, with $15 billion in potential growth capital and a robust pipeline of projects [1] Group 1: Financial Performance and Growth Outlook - WMB has raised its long-term adjusted EBITDA growth target from 5-7% to over 10% CAGR for 2025-2030, following a 9% CAGR from 2020 to 2025 [1] - The company expects U.S. natural gas demand to grow by 39 billion cubic feet per day (Bcf/d) by 2035, with 20 Bcf/d attributed to LNG exports and 10 Bcf/d for power generation [1] - For 2026, WMB has provided an adjusted EBITDA guidance range of $8.05–$8.25 billion, indicating a 6% growth relative to 2025 at the midpoint [1] Group 2: Power Projects - WMB has announced a new 340-megawatt natural gas power project in Ohio, with a 10-year agreement expected to be operational in the second half of 2028 [1] - The company has a backlog of power opportunities that is three times the combined gigawatts of its four sanctioned projects, totaling 6 gigawatts [1] - WMB is investing over $7 billion in its power projects, which are expected to yield a 20% return based on a 5x multiple [1] Group 3: Transmission Projects - WMB currently has 13 transmission projects underway, representing 7.1 Bcf/d of capacity, and is on track to increase delivery capacity by over 20% from 2025 to 2030 [1] - The transmission backlog has grown by over 5 Bcf/d in the past year, translating to more than $3 billion in capital expenditure [1] - WMB's transmission segment, particularly the Transco pipeline, is a key asset, transporting approximately 15% of the nation's natural gas [1]

Core Insights - Strata Critical Medical is a market leader in the non-correlated transplant industry, experiencing significant transformation that enhances organ recovery and increases demand for clinical and logistical support [3][5] - The company aims for a high-teens Adjusted EBITDA compound annual growth rate (CAGR) in the medium term, with potential for substantial growth through acquisitions [3][4][5] - Strata's integrated organ recovery platform is designed to be efficient and cost-effective, allowing for faster organ recovery processes and expanded service delivery [3][5] Financial Guidance - For 2026, Strata projects revenue between $255 million and $270 million, with Adjusted EBITDA expected to be between $28 million and $32 million [6] - The company anticipates organic revenue growth at a low double-digit CAGR and an Adjusted EBITDA margin of approximately 13.0% by 2029 [6] - Strata has approximately $200 million in cash available for deployment through 2029, targeting a doubling of Adjusted EBITDA by that year [4][6] Market Position and Strategy - Strata operates one of the largest air transport and surgical services networks for transplant hospitals and organ procurement organizations in the U.S. [9] - The company is well-positioned to outpace market growth while expanding its margins, driven by multiple catalysts in the industry [5] - The focus on acquisitions in a fragmented market is not only aimed at financial returns but also at enhancing local service delivery and reducing costs for customers [3][5]

Financial Data and Key Metrics Changes - Bausch Health reported a year-over-year revenue growth of 7% on a reported basis and 5% on an organic basis, achieving $2.681 billion in revenue for the third quarter [4][8] - Adjusted EBITDA increased by 8% year-over-year to $986 million, with an adjusted gross margin of 72.7%, which is 40 basis points lower than the previous year [8][9] - The company reduced its debt by approximately $600 million, leading to an increase in full-year guidance for revenue, adjusted EBITDA, and adjusted operating cash flow [5][15] Business Line Data and Key Metrics Changes - The Solta Medical segment saw a remarkable 25% growth on a reported basis and 24% on an organic basis, while Salix delivered 12% growth on a reported basis and 11% on an organic basis [6][10] - Xifaxan revenue grew 16% in the third quarter, with volume up 9%, driven by strong performance in the hepatology segment [10][20] - The diversified segment experienced a revenue decrease of 4% on a reported basis and 6% on an organic basis, primarily due to challenges in the neurology business [13][14] Market Data and Key Metrics Changes - International segment revenues decreased by 2% on a reported basis and 4% on an organic basis, with mixed performance across geographies [11] - EMEA led the international segment with a 12% increase, while Canada and LATAM contracted by 8% and 17%, respectively [11] - The Asia-Pacific region contributed significantly to Solta Medical's growth, with South Korea achieving 96% growth year-over-year [12][22] Company Strategy and Development Direction - The company is focused on five strategic priorities: people, growth, efficiency, innovation, and unlocking value, which guide its vision for the future [18] - Bausch Health aims to enhance its operational assets and continue executing its innovation and profitable growth agenda [16][18] - The acquisition of DURECT Corporation is expected to complement the existing portfolio and enhance the R&D pipeline, particularly in hepatology [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic macro backdrop and highlighted strong operational performance [5][18] - The company anticipates continued growth in its key segments, particularly in Xifaxan and Solta Medical, while also preparing for the impact of CMS pricing negotiations [19][33] - Full-year guidance has been raised, reflecting positive trends across the portfolio, with revenue expected between $5 billion and $5.1 billion [15][16] Other Important Information - The company exited the 340B program and Medicaid drug rebate program to optimize sales channels and enhance patient assistance programs [61][62] - The focus remains on deleveraging the business and optimizing the capital structure, with plans to use free cash flow for debt servicing [66][68] Q&A Session Summary Question: Revenue growth for Xifaxan outpacing script growth - Management explained that the disconnect is due to a one-time benefit associated with gross-to-net accrual and strong new patient starts [30][32] Question: Dynamics of CMS pricing negotiations - Management confirmed ongoing fruitful negotiations with CMS and expects pricing to be published on November 30, 2025 [33][34] Question: Revised guidance and one-time factors - Management acknowledged one-time adjustments in Q3 but emphasized positive trends across the portfolio [40][41] Question: SG&A spending and future run rates - Management indicated that Q3 SG&A was unusually low due to non-recurring accrual changes, suggesting Q1 and Q2 as better indicators for future spending [42][43] Question: RED-C phase 3 results timeline - Management confirmed that both phase 3 studies will have a combined readout in early 2026, which will be the final readout for the program [45][46] Question: Impact of exiting the 340B program - Management highlighted the decision was made to optimize sales channels and enhance patient assistance programs [62][63] Question: Debt refinancing and deleveraging strategies - Management outlined plans to use free cash flow for debt servicing and mentioned potential asset sales as a means to support deleveraging [66][68]

Core Insights - Flotek Industries (FTK) is on track to achieve 10 consecutive quarters of improved adjusted EBITDA, a notable achievement for a smaller energy company [1][9] - The company has transformed its financial health from a loss of $5.1 million in late 2022 to a gain of $7.8 million in Q1 2025, demonstrating effective management and execution [1][9] - FTK's adjusted EBITDA increased by 93% year-over-year in Q1 2025, alongside improved profit margins and reduced SG&A costs to 11% of revenues [2][9] - The company forecasts an 80% growth in EBITDA for 2025, driven by new contracts and international chemistry sales [3][9] Peer Performance - RPC Inc. reported Q1 2025 EBITDA of $48.9 million, a sequential increase of 6%, with an adjusted EBITDA margin of 14.7% [4] - ProPetro Holding achieved adjusted EBITDA of $73 million in Q1 2025, up 38% from the previous quarter, supported by a focus on next-generation fleet and disciplined capital spending [5] Market Performance - Flotek's shares surged by 55% in the first half of the year, reflecting strong investor interest [8] - The company trades at a forward price-to-earnings ratio of approximately 22, indicating a favorable valuation in the market [10]

Financial Performance & Guidance - First quarter 2025 adjusted EBITDA was approximately $1.8 billion[25] - The company reported net income attributable to ONEOK of $636 million, or $1.04 per diluted share[26] - ONEOK reaffirmed its 2025 adjusted EBITDA guidance midpoint of $8.225 billion[12, 23] - The company anticipates >15% EPS growth in 2026 and is approaching 10% adjusted EBITDA growth[23] Segment Performance (Q1 2025 vs Q4 2024) - Natural Gas Liquids adjusted EBITDA decreased, including an $82 million decrease from unconsolidated affiliates and a $72 million decrease in transportation and storage[30] - Natural Gas Gathering and Processing adjusted EBITDA increased, including a $13 million increase due to adjusted EBITDA from EnLink[31] - Refined Products and Crude adjusted EBITDA decreased[28] - Natural Gas Pipelines adjusted EBITDA decreased, including a $264 million decrease due to the interstate natural gas pipeline divestiture in 2024[31] Operational Highlights - Natural Gas Liquids: Gulf Coast/Permian NGL raw feed throughput increased by 13% compared to the fourth quarter of 2024[37] - Refined Products and Crude: Crude oil volume shipped increased to 1,846,000 bpd in the first quarter of 2025[40] - Natural Gas Gathering and Processing: Total processed volumes reached 5,250 MMcf/d in the first quarter of 2025[45] Growth Projects & Opportunities - The company is focused on high-return organic growth projects, including expansions of the West Texas NGL Pipeline (capacity to 740,000 bpd) and Elk Creek NGL Pipeline (capacity to 435,000 bpd)[56] - ONEOK sees opportunities in natural gas pipelines driven by industrial demand growth from data centers, LNG, and ammonia facilities[52, 55]

Financial Data and Key Metrics Changes - In Q1 2025, global shipments grew by 6% and adjusted EBITDA increased by 16% compared to the prior year, exceeding initial guidance [6][25]. - The company ended the quarter with a liquidity position of $570 million, reflecting a seasonal working capital outflow [20]. - Net leverage improved to 5.5 times net debt over the last twelve months adjusted EBITDA, down from 6.2 times reported in Q1 2024 [21][22]. Business Line Data and Key Metrics Changes - In Europe, Q1 revenue increased by 10% to $528 million, with shipments growing by 5% [13][14]. - In the Americas, revenue rose by 12% to $740 million, with adjusted EBITDA increasing by 16% to $106 million [15][16]. - North America shipments increased by 8%, driven by strong demand for nonalcoholic beverages, particularly energy drinks [16]. Market Data and Key Metrics Changes - The beverage can continues to gain market share in customers' packaging mix, with strong trends in customer innovation favoring beverage cans [9][26]. - In Brazil, beverage can shipments increased by 4%, outperforming the industry, which grew modestly [17]. - The company anticipates a low to mid-single-digit percentage growth in shipments for Brazil for 2025, maintaining a cautious outlook [18][19]. Company Strategy and Development Direction - The company is upgrading its full-year guidance for shipments growth to 3% to 4%, up from the initial 2% to 3% [27]. - Full-year adjusted EBITDA is now expected to be in the range of $695 million to $720 million, reflecting improved underlying business performance and favorable currency outlook [27]. - The company is focusing on high-return projects to increase capacity and flexibility in Europe, indicating a proactive approach to meet future demand [70][120]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business despite a dynamic macro environment, with minimal anticipated impact from tariff measures [8][10]. - The company remains cautious about the back half of the year due to potential volatility in the macro environment [101][114]. - Management highlighted strong customer performance in North America, particularly in innovative beverage categories, as a key driver for the positive outlook [58][61]. Other Important Information - The company announced a quarterly ordinary dividend of $0.10 per share, with no changes to its capital allocation policy [24]. - The company expects adjusted free cash flow for 2025 to be at least $150 million, with maintenance CapEx around $135 million [22]. Q&A Session Summary Question: Trends in April and impact of tariffs - Management noted no change in order behavior in April and attributed the guidance upgrade to continued sales momentum, particularly in North America [32][34]. Question: Confidence in North American energy market - Management expressed confidence in the recovery of the energy category, noting broad-based growth across customer segments [37][39]. Question: Customer mix issues in Brazil - Management acknowledged volatility in Brazil but maintained a cautious outlook despite a positive start to the year [50][52]. Question: Competitive landscape and contract renewals - Management indicated no material risk to volumes or margins from the competitive environment, with discussions on contract renewals progressing well [86][88]. Question: Utilization rates and new capacity in Brazil - Management stated that North America is operating in the nineties for utilization rates, while Brazil remains complex with lower utilization [94][96]. Question: Free cash flow and leverage outlook - Management is optimistic about free cash flow generation and expects leverage to decrease by year-end, primarily through EBITDA growth [135].